Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

MiMedx Group (MDXG) Stock Price & Analysis

MDXG Stock Chart & Stats

$3.88-$0.09(-2.27%)
At close: 4:00 PM EDT
$4$4.53 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$3.79 - $3.99
52-Week Range
$3.03 - $7.97
Previous Close
$3.97
Volume
248.64K
Average Volume (3M)
1.42M
Market Cap
$566.19M
Enterprise Value
$558.94M
Total Cash (Recent Filing)
$120.79M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
0.39
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
0.02
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet And Liquidity

The debt-free position and substantial net cash provide MiMedx with financial flexibility as it navigates reimbursement pressure and funds product development. Limited leverage reduces interest burden and refinancing exposure, while liquidity can support operations, regulatory work, and strategic investments.

Surgical Growth And Portfolio Adoption

Surgical growth is an important durable offset to weakness in Wound Care, especially because volume gains were broad-based across multiple products. Continued adoption of AMNIOFIX, AMNIOEFFECT, particulate products, and G4Derm Plus can strengthen the company’s mix.

Margin Recovery And Cost Discipline

The sequential margin recovery indicates that cost-reduction initiatives, better throughput, and operating efficiencies can partially offset revenue pressure. Management’s expectation that fourth-quarter gross margin will approximate Q3 supports the potential for more stable profitability.

Bears Say

Wound Care Reimbursement And Demand Pressure

Wound Care remains a major structural headwind because reimbursement reductions are pressuring both pricing and utilization across the industry. Management also cannot yet identify a stable volume or pricing base, limiting visibility into when this business can recover.

Sharp Deterioration In Current Earnings

The steep year-over-year deterioration shows that cost savings have not yet offset lost revenue and lower Wound Care profitability. A return to losses weakens internal funding capacity and makes sustained earnings recovery dependent on Surgical growth and reimbursement stabilization.

Regulatory Delay To Sanara Acquisition

The extended FTC review creates uncertainty around when MiMedx can access Sanara’s products, markets, and expected synergies. A delayed closing could postpone the planned expansion of Surgical revenue and margins while transaction-related costs and financing fees continue.

MiMedx Group News

MDXG FAQ

What was MiMedx Group’s price range in the past 12 months?
MiMedx Group lowest stock price was $3.03 and its highest was $7.97 in the past 12 months.
What is MiMedx Group’s market cap?
MiMedx Group’s market cap is $566.19M.
When is MiMedx Group’s upcoming earnings report date?
MiMedx Group’s next earnings report is estimated for Mar 03, 2027 (not yet confirmed), which is in 121 days.
How were MiMedx Group’s earnings last quarter?
MiMedx Group released its earnings results on Oct 28, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.06.
Is MiMedx Group overvalued?
According to Wall Street analysts MiMedx Group’s price is currently Undervalued.
Does MiMedx Group pay dividends?
MiMedx Group does not currently pay dividends.
What is MiMedx Group’s EPS estimate?
MiMedx Group’s EPS estimate is 0.02.
How many shares outstanding does MiMedx Group have?
MiMedx Group has 145,925,600 shares outstanding.
What happened to MiMedx Group’s price movement after its last earnings report?
MiMedx Group reported an EPS of -$0.06 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went up 0.506%.
Which hedge fund is a major shareholder of MiMedx Group?
Hedge funds hold MiMedx Group shares: the largest hedge-fund position in MiMedx Group is 71,885,882 shares, and hedge funds increased their holdings by 226.6K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology